The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
Allakos Inc (ALLK)

Allakos is a clinical stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. Co.'s antibodies are lirentelimab (AK002) and AK006. Co. is developing lirentelimab for the treatment of eosinophilic gastritis/eosinophilic duodenitis, eosinophilic esophagitis, atopic dermatitis, chronic spontaneous urticaria and potentially additional indications. AK006 targets Siglec-6, an inhibitory receptor selectively expressed on various cells. AK006 appears to have the potential to provide various cell inhibition than lirentelimab.

ALLK SEC Filing Email Alerts Service

Company Name:  Allakos Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ALLK:  14
Total Market Value Held by ETFs:  $11.90M
Total Market Capitalization:  $189.00M
% of Market Cap. Held by ETFs:  6.30%
September 27, 2023    8:09 AM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree ALLK Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.62 out of 4)
9th percentile
(ranked lower than approx. 91% of all stocks covered)

Analysts' Target Price:
ALLK Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Allakos Inc (ALLK) Page | The Online Investor | | Copyright © 1998 - 2023, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.